Researchers have found that activating the ACE2/Ang1-7/Mas axis mitigates the metabolic dysfunction and prevents NAFLD [17, 18] mainly via improving hepatic IR and FFA oxidation along with inhibiting liver lipogenesis and inflammation [20–22]. The gene discussed is ACE2; the disease is metabolic dysfunction-associated steatotic liver disease.